IS5581A - New compounds and their use as positive direct AMPA receptors - Google Patents

New compounds and their use as positive direct AMPA receptors

Info

Publication number
IS5581A
IS5581A IS5581A IS5581A IS5581A IS 5581 A IS5581 A IS 5581A IS 5581 A IS5581 A IS 5581A IS 5581 A IS5581 A IS 5581A IS 5581 A IS5581 A IS 5581A
Authority
IS
Iceland
Prior art keywords
new compounds
positive direct
ampa receptors
ampa
receptors
Prior art date
Application number
IS5581A
Other languages
Icelandic (is)
Inventor
Haahr Gouliaev Alex
Larsen Mogens
Varming Thomas
Mathiesen Claus
Holm Johansen Tina
Scheel-Krüger Jørgen
M. Olsen Gunnar
Østergaard Nielsen Elsebet
Original Assignee
Neurosearch A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch A/S filed Critical Neurosearch A/S
Publication of IS5581A publication Critical patent/IS5581A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C07D285/26—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals
    • C07D285/28—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
IS5581A 1998-02-18 2000-08-04 New compounds and their use as positive direct AMPA receptors IS5581A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK22698 1998-02-18
PCT/DK1999/000070 WO1999042456A2 (en) 1998-02-18 1999-02-18 Novel compounds and their use as positive ampa receptor modulators

Publications (1)

Publication Number Publication Date
IS5581A true IS5581A (en) 2000-08-04

Family

ID=8091151

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5581A IS5581A (en) 1998-02-18 2000-08-04 New compounds and their use as positive direct AMPA receptors

Country Status (17)

Country Link
EP (1) EP1071426A2 (en)
JP (1) JP2002504481A (en)
CN (1) CN1293665A (en)
AU (1) AU751384B2 (en)
CA (1) CA2320354A1 (en)
EE (1) EE200000468A (en)
HU (1) HUP0101280A3 (en)
IL (1) IL137720A0 (en)
IS (1) IS5581A (en)
NO (1) NO20004121L (en)
NZ (1) NZ506251A (en)
PL (1) PL342843A1 (en)
RU (1) RU2214405C2 (en)
SK (1) SK11892000A3 (en)
TR (1) TR200002427T2 (en)
WO (1) WO1999042456A2 (en)
ZA (1) ZA991301B (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7671200B2 (en) 1999-10-27 2010-03-02 Cytokinetics, Inc. Quinazolinone KSP inhibitors
DE10004572A1 (en) * 2000-02-02 2001-08-09 Boehringer Ingelheim Pharma New positive allosteric AMPA receptor modulators (PAARM), processes for their production and their use as medicines
FR2812291B1 (en) * 2000-07-28 2002-12-13 Adir NOVEL BENZOTHIADIAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CN1314351A (en) * 2001-03-22 2001-09-26 刘志红 Process for synthesizing quinazolone and quinazolone compound with anti-cancer function
TWI232863B (en) 2001-06-11 2005-05-21 Akzo Nobel Nv Benzoxazepine derivatives
HUP0400196A3 (en) * 2001-06-14 2007-05-02 Organon Nv (pyrido/thieno)[f]oxazepin-5-one derivatives, their use and pharmaceutical compositions containing them
CA2458388A1 (en) * 2001-10-10 2003-04-17 Neurosearch A/S Novel benzothiazine derivatives, their preparation and use
MXPA04004815A (en) 2001-11-26 2005-02-17 Cortex Pharma Inc Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses.
FR2833950B1 (en) * 2001-12-21 2005-12-16 Servier Lab NOVEL BENZOTHIAZINE AND BENZOTHIADIAZINE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
FR2833956B1 (en) * 2001-12-21 2004-01-30 Servier Lab NOVEL BENZOTHIAZINE AND BENZOTHIADIAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2833955B1 (en) * 2001-12-21 2004-01-30 Servier Lab NOVEL BENZOTHIAZINE AND BENZOTHIADIAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2854634B1 (en) * 2003-05-05 2005-07-08 Servier Lab NOVEL THIADIAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2856064B1 (en) * 2003-06-13 2005-08-19 Servier Lab NOVEL BENZOTHIAZINE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2856065B1 (en) * 2003-06-13 2005-08-19 Servier Lab NOVEL BENZOTHIAZINE AND BENZOTHIADIAZINE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
WO2005005395A2 (en) 2003-07-02 2005-01-20 F. Hoffmann-La Roche Ag Arylamine-substituted quinazolinone compounds
AU2004270162B2 (en) 2003-08-28 2010-05-13 Nicox S.A. Nitrosated ad nitrosylated diuretic compouds, compositions and methods of use
US7244843B2 (en) 2003-10-07 2007-07-17 Bristol-Myers Squibb Company Modulators of serotonin receptors
FR2865474B1 (en) * 2004-01-26 2008-06-13 Servier Lab NOVEL FLUORINATED BENZOTHIAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2877338B1 (en) 2004-11-03 2007-01-26 Servier Lab NOVEL BENZOTHIADIAZINE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
FR2877342B1 (en) 2004-11-03 2007-01-26 Servier Lab NOVEL BENZOTHIADIAZINE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
FR2879201B1 (en) * 2004-12-10 2007-02-16 Servier Lab NOVEL BENZOTHIAZINE AND BENZOTHIADIAZINE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
WO2006086464A2 (en) 2005-02-10 2006-08-17 Bristol-Myers Squibb Company Dihydroquinazolinones as 5ht modulators
CA2597460A1 (en) 2005-02-24 2006-08-31 Nitromed, Inc. Nitric oxide enhancing diuretic compounds, compositions and methods of use
GB0507298D0 (en) * 2005-04-11 2005-05-18 Novartis Ag Organic compounds
TW200800959A (en) 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
AU2007342365B2 (en) 2007-01-03 2012-11-15 Les Laboratoires Servier 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
CL2008000119A1 (en) 2007-01-16 2008-05-16 Wyeth Corp COMPOUNDS DERIVED FROM PIRAZOL, ANTAGONISTS OF THE NICOTINIC ACETILCOLINE RECEIVER; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS SENILE DEMENTIA, ALZHEIMER AND SCHIZOPHRENIA.
JP5694765B2 (en) 2007-05-17 2015-04-01 コーテックス ファーマシューティカルズ， インコーポレイテッド Disubstituted amides for enhancing glutamatergic synaptic responses
US8119632B2 (en) 2007-08-10 2012-02-21 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
BRPI0814149A2 (en) 2007-08-10 2011-09-13 Cortex Pharma Inc compound, pharmaceutical composition, methods of treatment and use of the compound
FR2933698A1 (en) 2008-07-09 2010-01-15 Servier Lab NOVEL CYCLOALKYLATED BENZOTHIADIAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2943342B1 (en) 2009-03-20 2011-03-04 Servier Lab NOVEL BENZOTHIADIAZEPINES DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
PT2464645T (en) 2009-07-27 2017-10-11 Gilead Sciences Inc Fused heterocyclic compounds as ion channel modulators
FR2955107B1 (en) 2010-01-08 2012-03-02 Servier Lab NOVEL THIOCHROMAN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
FR2955106B1 (en) 2010-01-08 2011-12-23 Servier Lab NOVEL CYCLOPROPYLATED BENZOTHIADIAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
BR112012033402A2 (en) 2010-07-02 2017-01-24 Gilead Sciences Inc ion channel modulators according to fused heterocyclic compounds
CN102958919A (en) * 2010-07-02 2013-03-06 霍夫曼-拉罗奇有限公司 Novel tetrahydroquinoline derivatives
FR2964969B1 (en) * 2010-09-16 2012-08-24 Servier Lab NOVEL DIHYDROBENZOXATHIAZEPINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
IT1402905B1 (en) * 2010-11-29 2013-09-27 Univ Degli Studi Modena E Reggio Emilia DERIVATIVES OF 1,2,4-BENZOTIADIAZIN 1,1-DIOXIDE, THEIR PREPARATION AND THEIR USE AS ALLOSTERIC MODULATORS OF THE AMPA RECEPTOR.
BR112013028886A2 (en) 2011-05-10 2016-08-09 Gilead Sciences Inc fused heterocyclic compounds as sodium channel modulators
UY34171A (en) 2011-07-01 2013-01-31 Gilead Sciences Inc FUSIONED HETEROCYCLIC COMPOUNDS AS IONIC CHANNEL MODULATORS
NO3175985T3 (en) 2011-07-01 2018-04-28
CN102977054A (en) * 2012-12-12 2013-03-20 中国药科大学 Application of selective alpha2A receptor stimulant in treating alzheimer disease
BR112015030095B1 (en) 2013-05-30 2023-02-28 Idorsia Pharmaceuticals Ltd CXCR7 RECEIVER MODULATORS
JO3316B1 (en) 2013-05-30 2019-03-13 Lilly Co Eli 3,4-dihydroisoquinolin-2(1h)-yl compounds
CN103275016B (en) * 2013-06-04 2015-03-11 温州医科大学附属第二医院 Synthetic method of 2-subsituted quinazoline compounds
BR112015031249A2 (en) 2013-06-13 2017-07-25 Veroscience Llc treatment method, method for treating a metabolic disorder or a key element thereof, method for normalizing a daily dopamine release rate in the sumn, method for stimulating dopamine release from dopaminergic neurons in an individual's sumn and pharmaceutical composition
CN103319381B (en) * 2013-06-14 2014-08-27 湖州康企药业有限公司 Preparation method of high-purity fine sulfanilamide
CN103772296B (en) * 2013-12-19 2015-06-17 安徽师范大学 Synthesis method for quinazoline derivative
CA2963447A1 (en) 2014-12-01 2016-06-09 Actelion Pharmaceuticals Ltd Cxcr7 receptor modulators
CN105294599B (en) * 2015-09-17 2017-09-22 三峡大学 A kind of diazthines compound and its asymmetric synthetic method
CN106946920A (en) * 2017-04-05 2017-07-14 泰力特医药（湖北）有限公司 A kind of preparation method of 4 amino phenyl boronic acid derivative
WO2020253862A1 (en) * 2019-06-21 2020-12-24 上海翰森生物医药科技有限公司 Nitrogen-containing aryl phosphorus oxide derivative, preparation method therefor and use thereof
RU2726456C1 (en) * 2019-10-02 2020-07-14 Общество с ограниченной ответственностью "Научно-исследовательский институт ХимРар" (ООО "НИИ ХимРар") Hepatitis b virus (hbv) inhibitor
CN111100042B (en) * 2019-11-18 2022-05-31 苏州诚和医药化学有限公司 Preparation method of 2-methoxy-5-sulfonamide benzoic acid
CN111018750B (en) * 2019-12-19 2022-05-27 苏州诚和医药化学有限公司 Novel preparation method of 2, 3-dimethoxy-5-sulfamide benzoic acid
WO2024141660A2 (en) * 2022-12-30 2024-07-04 Aexon Labs. Inc. Dihydro-quinazoline, -benzothiazine and -benzoxazine derivatives and use thereof as orexin receptors agonists for treating or preventing neurological diseases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3275625A (en) * 1966-09-27 Derivatives of
NL296964A (en) *
FR1217929A (en) * 1958-03-03 1960-05-06 Ciba Geigy Process for the preparation of 6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide and its salts
GB863474A (en) * 1958-08-13 1961-03-22 Knud Abildgaard Benzothiadiazine derivatives and their preparation
DE1125938B (en) * 1960-02-12 1962-03-22 Thomae Gmbh Dr K Process for the preparation of 7-sulfamyl-3, 4-dihydro-1, 2, 4-benzothiadiazine-1, 1-dioxydes
GB946864A (en) * 1960-05-06 1964-01-15 Knud Abildgaard Method for the production of 3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxides
US3419552A (en) * 1961-04-12 1968-12-31 Lilly Co Eli Preparation of substituted dihydrobenzothiadiazine-1,1-dioxides
CH475269A (en) * 1962-04-19 1969-07-15 Hans Voigt Chem Pharm Fabrik D Process for the preparation of 7-sulfonamido-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxydes
US3351595A (en) * 1962-12-07 1967-11-07 Ciba Geigy Corp Derivatives of 3, 4-dihydro-2h-1, 2, 4-benzothiadiazine-1, 1-dioxide
US3311620A (en) * 1963-05-31 1967-03-28 Stanley C Bell Fused ring benzothiadiazines
US3277086A (en) * 1964-07-07 1966-10-04 American Home Prod 1, 2, 4-benzothiadiazine 1, 1-dioxides having a heterocyclic ring fused to the "b" face thereof
US4184039A (en) * 1977-12-01 1980-01-15 Paul Finkelstein Benzothiadiazine 1, 1-dioxides
AU3957093A (en) * 1992-04-15 1993-11-18 Rhone-Poulenc Rorer S.A. 3,4-dihydro-2H-1,2,4-benzothiadiazine-1,1-dioxide-3-carboxyl ic acid derivatives, preparation thereof and drugs containing same
US5488049A (en) * 1993-12-10 1996-01-30 Fidia - Georgetown Institute For The Neuro-Sciences Method of treating learning and memory disorders using benzothiadiazide derivatives as nootropic agents
FR2722502B1 (en) * 1994-07-12 1996-08-23 Adir NOVEL BENZOTHIADIAZINE DERIVATIVE, ITS PREPARATION METHOD AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
AU709113B2 (en) * 1996-01-29 1999-08-19 Regents Of The University Of California, The Method for treating sexual dysfunctions
WO1998012185A1 (en) * 1996-09-17 1998-03-26 The Regents Of The University Of California Benzothiadiazide derivatives and their use as allosteric up-modulators of the ampa receptor

Also Published As

Publication number Publication date
EE200000468A (en) 2002-04-15
TR200002427T2 (en) 2001-01-22
NO20004121D0 (en) 2000-08-17
CA2320354A1 (en) 1999-08-26
IL137720A0 (en) 2001-10-31
WO1999042456A3 (en) 1999-10-07
JP2002504481A (en) 2002-02-12
ZA991301B (en) 1999-09-13
NZ506251A (en) 2003-01-31
WO1999042456A2 (en) 1999-08-26
CN1293665A (en) 2001-05-02
AU751384B2 (en) 2002-08-15
NO20004121L (en) 2000-10-17
EP1071426A2 (en) 2001-01-31
HUP0101280A3 (en) 2003-02-28
PL342843A1 (en) 2001-07-16
SK11892000A3 (en) 2001-02-12
HUP0101280A2 (en) 2001-10-28
AU2512399A (en) 1999-09-06
RU2214405C2 (en) 2003-10-20

Similar Documents

Publication Publication Date Title
IS5581A (en) New compounds and their use as positive direct AMPA receptors
IS5699A (en) New use
ID25977A (en) DIAPON ONCE USE
ID24555A (en) DIAPON ONCE USE
ID26186A (en) SAMPO COMPOSITION
ID28694A (en) SAMPO COMPOSITION
ID29430A (en) HERBISIDE COMPOSITION
FI4209U1 (en) New compounds
NO990113D0 (en) Multihull-speed ° y
ID23458A (en) NEFAZODON AVAILABLE FORM
DE69942892D1 (en) GAS-CREATING COMPOSITION
ID23083A (en) DIAPON ONCE USE
DE59904577D1 (en) metallocene
ID27845A (en) TETRAHIDROKUILINA DECREASED AS GLISILINA ANTAGONISTS
NO20010154L (en) Well Hulls-tension swivel time
NO990717D0 (en) Monitor st ° ttemekanisme
ID26295A (en) HARD-ULTRAVIOLET COMPOSITION
ID26485A (en) PAROXOXINE COMPOSITION
ID28359A (en) COMPOSITION
DE69939964D1 (en) Gel-shaped composition
ID28785A (en) COMPOSITION
SE9800472D0 (en) New use
SE9803098D0 (en) new use
SE9802610D0 (en) New use
SE9804020D0 (en) New use